Small Molecule Pharmaceuticals

UB-941，BRAF Kinase Inhibitor

The "B RAF-MEK-ERK" signaling pathway plays a crucial role in controlling cell proliferation, differentiation, and survival. Mutations in the B-Raf gene are found in approximately 7% of human cancers. One particularly significant mutation is the substitution of Valine (V) with Glutamic Acid (E) at the 600th amino acid position, known as the B-Raf V600E mutation. This mutation has been shown to enhance B-Raf activity by over 500-fold, leading to sustained cellular proliferation and ultimately carcinogenesis. Drawing upon its exceptional capabilities in new drug development and extensive experience in cGMP drug manufacturing, UBI Pharma Inc. has been granted the global exclusive license for "BRAF Kinase Inhibitor (UB-941)" by DCB, a biotechnology development center, to enter the field of targeted cancer therapy and contribute significantly to this area.

Market Potential

The market for BRAF kinase inhibitors was valued at USD 924.8 million in 2020 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.6% during the forecast period (2020-2027).